SOD1 and amyotrophic lateral sclerosis: The principle of targeting SOD1 expression with AAV-mediated down-regulation of malign SOD1 variants gained further support from a recently completed compassionate-use study in two SOD1-ALS male patients aged 22 and 56 years old (Mueller et al., 2020).